ischemia is an incomplete gauge of the myocardial 02 demand present at the time. Perhaps the apparent changes in "ischemic threshold" during the day described by Tzivoni and colleagues3 may be explained in part by fluctuations in the baseline heart rate or the duration of heart rate increases at different times of the day rather than solely to changes in coronary tone, as the investigators suggest.
Unfavorable Outcome in Patients With Primary Electrical Disease Who Survive Ventricular Fibrillation
The study by Wever et all highlights several important features regarding patients with primary electrical disease: (1) noninducibility at baseline electrophysiological study does not necessarily predict an arrhythmia-free course; (2) such patients are at fairly high risk of major arrhythmic events during follow-up; (3) defibrillator implantation should be considered as an early management strategy. Interestingly, 2 of their 19 patients experienced ventricular fibrillation (VF)/sudden cardiac death despite receiving what was thought to be suppressive therapy (one gauged by electrophysiological study, the other by noninvasive means). The authors treated 10 of their 19 patients with an automatic (A) implantable cardioverter-defibrillator (ICD) and highly recommended that a defibrillator be implanted early in all patients with primary electrical disease who have survived VE. Their findings corroborate those of our earlier study, the first and largest systematic study of ICD therapy in VF survivors without significant structural heart disease (28 patients). 23 The study of Wever et al was a single-center, prospective one, whereas ours was a multicenter, retrospective one that by design included only patients without significant structural heart disease treated with ICDs. In the study of The precise number and timing (relative to index arrest and date of ICD implantation) of recurrent AICD shocks in patients 7, 8, and 10 of the study by Wever et al could not be determined from the data provided. Were these all part of one shock episode, respectively? Interestingly, none of the patients in Wever's study received "undetermined" shocks, whereas the majority of shocks in our population were classified as "indeterminate." Several factors may account for the difference. Wever et al defined an appropriate shock to include one preceded by sudden onset of palpitations. By this definition, at least three and possibly five of our patients' shocks would have been reclassified from indeterminate to appropriate. Programmed AICD rate cutoffs in our patients were not always set at 200 beats per minute, and, although set above maximum exercise rates, may initially still have been set lower than the heart rates ultimately achieved during vigorous activity by many of these otherwise healthy patients. The role, if any, of P-adrenergic blocking agents is uncertain. Several of our patients but apparently none of Wever's patients were receiving these drugs.
In summary, despite some methodological differences, the study by Wever et al corroborates our earlier findings concerning patients with VF in the absence of significant structural heart disease: These are patients with a risk of recurrent arrest whose fatal outcome may be avoided by ICD therapy. Baseline and posttreatment noninducibility assessed by electrophysiological or noninvasive studies does not necessarily portend an arrhythmiafree outcome.
It is hoped that our study and that of Wever et al provide complementary information that will help physicians in the optimal management of these challenging patients with idiopathic VF. (25%) and proANF 1-98 (the N-terminus of the ANF prohormone, 75%) in plasma as determined by high-performance gel permeation chromatography,5 whereas our proANF 31-67 assay immunologically recognizes proANF 31-67 (96%) and proANF (4%).3 Thus, each of these atrial natriuretic peptides is stable in plasma for prolonged periods if stored at -80°C. Tan et all6 and Nelesen et al7 both have shown that frequent thawing and refreezing of plasma samples degrade atrial natriuretic peptides and decrease their measured concentrations. This is an important point to remember when assaying plasma for the concentration of these peptides.
As opposed to the above stability of atrial natriuretic peptides in plasma samples, when the pure human or rat sequenced atrial M D Meissner
